Publication:
Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats

dc.contributor.authorAksit, Dilek
dc.contributor.authorYalinkilinc, Hande Sultan
dc.contributor.authorSekkin, Selim
dc.contributor.authorBoyacioglu, Murat
dc.contributor.authorAyaz, Erol
dc.contributor.authorGokbulut, Cengiz
dc.contributor.buuauthorCirak, Veli Yilgor
dc.contributor.departmentVeteriner Fakültesi
dc.contributor.departmentKlinik Öncesi Bilimler Bölümü
dc.contributor.orcid0000-0003-0570-2514
dc.contributor.researcheridFYC-2043-2022
dc.contributor.scopusid6602404057
dc.date.accessioned2023-10-06T05:19:07Z
dc.date.available2023-10-06T05:19:07Z
dc.date.issued2015-12-12
dc.description.abstractBackground: The aims of this study were to compare the pharmacokinetics of albendazole sulfoxide (ABZ-SO, ricobendazole) in goats and sheep at a dose of 5 mg/kg bodyweight (BW), after intravenous (IV) and subcutaneous (SC) administrations, and to investigate the effects of increased doses (10 and 15 mg/kg BW) on the plasma disposition of ABZ-SO in goats following SC administration. A total of 16 goats (Capra aegagrus hircus, eight males and eight females) and 8 sheep (Ovis aries, four males and four females) 12-16 months old and weighing 20-32 kg, were used. The study was designed according to two-phase crossover study protocol. In Phase-1, eight sheep were assigned as Group I and 16 goats were allocated into two groups (Group II and Group III). ABZ-SO was applied to Group I (sheep) and Group II (goats) animals subcutaneously, and to Group III (goats) animals intravenously, all at a dose rate of 5 mg/kg BW. In Phase-2, the sheep in the Group I received ABZ-SO intravenously in a dose of 5 mg/kg BW; the goats in Group II and Group III received ABZ-SO subcutaneously at a dose of 10 mg/kg and 15 mg/kg BW, respectively. Blood samples were collected from the jugular vein at different times between 1 and 120 h after drug administrations. The plasma concentrations of ABZ-SO and its metabolites were analysed by high performance liquid chromatography. Results: In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of 5 mg/kg BW. On the other side, dose-dependent plasma dispositions of ABZ-SO were observed following SC administration at increased doses (10 and 15 mg/kg) in goats. Conclusions: Consequently, ABZ-SO might be used at higher doses to provide higher plasma concentration and thus to achieve greater efficacy against the target parasites.
dc.identifier.citationAksit, D. vd. (2015). "Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats". BMC Veterinary Research, 11(1)
dc.identifier.issn1746-6148
dc.identifier.issue1
dc.identifier.pubmed26012791
dc.identifier.scopus2-s2.0-85019263294
dc.identifier.urihttps://doi.org/10.1186/s12917-015-0442-5
dc.identifier.urihttps://bmcvetres.biomedcentral.com/articles/10.1186/s12917-015-0442-5
dc.identifier.urihttp://hdl.handle.net/11452/34230
dc.identifier.volume11
dc.identifier.wos000355077700001
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherBMC
dc.relation.collaborationYurt içi
dc.relation.journalBMC Veterinary Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.relation.tubitak109 O 862
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectVeterinary sciences
dc.subjectBenzimidazoles
dc.subjectAlbendazole
dc.subjectAlbendazole sulfoxide
dc.subjectPharmacokinetics
dc.subjectEnantiomers
dc.subjectSheep
dc.subjectGoat
dc.subjectDairy goats
dc.subjectEnantiomers
dc.subjectRicobendazole
dc.subjectMetabolites
dc.subjectFenbendazole
dc.subjectOxfendazole
dc.subjectNetobimin
dc.subjectBehavior
dc.subjectPharmacology
dc.subjectFormulation
dc.subjectBenzimidazoles
dc.subjectSheep
dc.subjectAnimalia
dc.subjectCapra hircus
dc.subjectOvis aries
dc.subject.emtreeAlbendazole
dc.subject.emtreeAlbendazole sulfoxide
dc.subject.emtreeAnthelmintic agent
dc.subject.emtreeAnalogs and derivatives
dc.subject.emtreeAnimal
dc.subject.emtreeArea under the curve
dc.subject.emtreeBlood
dc.subject.emtreeDose response
dc.subject.emtreeFemale
dc.subject.emtreeGoat
dc.subject.emtreeHalf life time
dc.subject.emtreeIntravenous drug administration
dc.subject.emtreeMale
dc.subject.emtreeMetabolism
dc.subject.emtreeSheep
dc.subject.emtreeSpecies difference
dc.subject.emtreeSubcutaneous drug administration
dc.subject.meshAdministration, Intravenous
dc.subject.meshAlbendazole
dc.subject.meshAnimals
dc.subject.meshAnthelmintics
dc.subject.meshArea under curve
dc.subject.meshDose-response relationship, Drug
dc.subject.meshFemale
dc.subject.meshGoats
dc.subject.meshHalf-life
dc.subject.meshInjections, Subcutaneous
dc.subject.meshMale
dc.subject.meshSheep
dc.subject.meshSpecies specificity
dc.subject.scopusAlbendazole; Benzimidazole; Anthelmintic agent
dc.subject.wosVeterinary sciences
dc.titleComparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats
dc.typeArticle
dc.wos.quartileQ1
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentVeteriner Fakültesi/Klinik Öncesi Bilimler Bölümü
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: